1. Home
  2. CDT vs LRHC Comparison

CDT vs LRHC Comparison

Compare CDT & LRHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Conduit Pharmaceuticals Inc.

CDT

Conduit Pharmaceuticals Inc.

HOLD

Current Price

$1.66

Market Cap

2.9M

Sector

Health Care

ML Signal

HOLD

Logo La Rosa Holdings Corp.

LRHC

La Rosa Holdings Corp.

HOLD

Current Price

$0.81

Market Cap

2.9M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
CDT
LRHC
Founded
2019
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9M
2.9M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
CDT
LRHC
Price
$1.66
$0.81
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
415.3K
302.6K
Earning Date
03-27-2026
11-19-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$78,660,186.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
24.52
52 Week Low
$1.48
$0.75
52 Week High
$2,198.40
$95.20

Technical Indicators

Market Signals
Indicator
CDT
LRHC
Relative Strength Index (RSI) 41.91 19.81
Support Level $1.61 $0.75
Resistance Level $1.89 $2.25
Average True Range (ATR) 0.21 0.27
MACD -0.00 0.05
Stochastic Oscillator 20.00 4.00

Price Performance

Historical Comparison
CDT
LRHC

About CDT Conduit Pharmaceuticals Inc.

CDT Equity Inc, formerly Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

About LRHC La Rosa Holdings Corp.

La Rosa Holdings Corp operates in the U.S. residential real estate market. It is a holding company for agent-centric, technology-integrated, cloud-based, multi-service real estate companies. The company's business is organized based on the services it provides internally to the agents and to the public, which are residential and commercial real estate brokerage, franchising, real estate brokerage education and coaching, and property management. The company has six reportable segments, namely: Real Estate Brokerage Services (Residential), Franchising Services, Coaching Services, Property Management, Real Estate Brokerage Services (Commercial), and Title Settlement and Insurance. It derives maximum revenue from the Real Estate Brokerage Services (Residential) segment.

Share on Social Networks: